GForce-PD News

Another way to dial back stem cell hype (but not hope): Put a dollar figure on it

posted in: Sidebar | 0

Another way to dial back stem cell hype (but not hope): Put a dollar figure on it

In an effort to reign in the hype surrounding stem cell research that has led to a proliferation of unapproved and potentially dangerous stem cell therapies, the International Society for Stem Cell Research (ISSCR) recently released updated guidelines outlining conduct for stem cell researchers that, for the first time, included communications activities.

Good to see responsible interpretation of the data

posted in: Sidebar | 0

StemCells, Inc. Announces Termination of Phase II Pathway Study Following Review of Data

NEWARK, Calif., May 31, 2016 (GLOBE NEWSWIRE) — StemCells, Inc. (NASDAQ: STEM) (the “Company”) today announced its decision to terminate the Company’s Phase II Pathway Study in spinal cord injury following an in-depth review of data from the study and after obtaining the concurrence of the study’s Interim Analysis Data Monitoring Committee (the “IA-DMC”).

National Stem Cell Foundation and Michael J. Fox Foundation Partner to Support Parkinson’s Cell Replacement Therapy

posted in: Sidebar | 0

National Stem Cell Foundation and Michael J. Fox Foundation Partner to Support Parkinson’s Cell Replacement Therapy

LOUISVILLE and NEW YORK, May 25, 2016 /PRNewswire-USNewswire/ — The National Stem Cell Foundation (NSCF) and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) have announced a partnership to fund development of a cutting-edge therapy to replace the dopamine neurons that degenerate in Parkinson’s disease, the second most common brain disease after Alzheimer’s.

Asterias Biotherapeutics Announces Positive New Long-Term Follow-Up Results for AST-OPC1

posted in: Sidebar | 0

Asterias Biotherapeutics Announces Positive New Long-Term Follow-Up Results for AST-OPC1

Data Included in Newly Submitted Patent Application for AST-OPC1- FREMONT, Calif. May 24, 2016 – Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced new positive long-term follow-up results from its Phase 1 clinical trial assessing the safety of AST-OPC1 (oligodendrocyte progenitor cells) in patients with spinal cord injury.

GForce-PD Facebook Feed

We look back to an exciting meeting of the GForce-PD group in kyoto. Strong progress from all groups. ...

View on Facebook

GForce-PD updated their cover photo. ...

View on Facebook